Lytix Biopharma announces two recent publications on LTX-401, an oncolytic molecule developed for visceral tumors.

A preclinical study, performed together with collaborating research group at Institut Gustave Roussy, France, demonstrates that combining LTX-401 with checkpoint inhibitors results in strong systemic antitumor effects. (See article.)

Another study, in collaboration with Oslo University Hospital, describes the effect of of LTX-401 in an ortotopic liver cancer model. The study demonstrates complete tumor regression and systemic immune response in the majority of the treated animals. (See article.)